麻豆AV

Currently, subject-level prediction of AD risk is in its infancy. Prediction of AD-related neuro- degeneration relies on various biological markers (biomarkers), including changes in the cerebrospinal levels of tau protein and amyloid 尾 (6), having the 蔚4 genetic allele of the apolipoprotein E protein (APOE4) (7), reduced hippocampal volume and cortical thickness (2,8,9), as well as clinical diagnosis of mild cognitive impairment (MCI) (2,10). Some supervised machine learning (ML) efforts attempted to predict patients鈥� clinical diagnosis at a future time-point (8,11鈥� 13), yielding reasonable accuracies. However, they only focus on whether a currently MCI patients will later receive a 鈥渄ementia鈥� diagnosis. We argue that using clinical diagnosis as label offer only coarse ideas regarding cognitive abilities. Instead, our group had success using cognitive assessments scores to discover clinical sub-groups, before using the sub-group labels as prediction goals for ML (4). The goal of my project, supervised by Dr. Chakravarty, is to improve discovery and modelling of clinical sub-groups in AD, using cognitive assessment scores.

We used unsupervised clustering for our sub-group discovery, a method which group together subjects with similar characteristics (i.e. features). The unsupervised methodology is independent of human assumptions, meaning the clusters are discovered in a completely data-driven fashion. Specifically, clinical sub-groups are modelled by clustering together subjects with similar cognitive trajectories, measured by the changes in cognitive assessment scores over time. We use longitudinal data obtained from the Alzheimer鈥檚 Disease Neuroimaging Initiative database (adni.loni.usc.edu). Our previous work modelled using only a single cognitive score (4). I expanded this to include three scores: the Alzheimer鈥檚 Disease Assessment Scale (ADAS-13) (14), Mini-Mental State Examination (MMSE) (15), and the Montreal Cognitive Assessment (MoCA) (16). They are commonly used to assess functional impairment associated with AD, and construct a holistic personalized cognitive profile at a resolution unobtainable from clinical diagnosis alone.

In the dataset, subjects have cognitive assessments measured at different timepoints, making acquiring a time-standardized dataset for unsupervised clustering difficult. Consequently, we tested multiple models, each with different ways of generating standardized subject features. The most successful model combined linear regression and unsupervised clustering. A degree 1 polynomial (i.e. line) is fitted to each subject, before the slope coefficient is used as features in an unsupervised clustering task (using Hierarchical clustering). Using this, we extracted 3 clusters, each showing a visually distinct trajectory (Figure 1), defined as rapid decline, slow decline and stable.

In addition to the visual separation of group trajectories, we quantitatively evaluated the between- cluster frequency of APOE4 alleles, which is the best-known genetic risk factor for AD. Reasonably, the above model showed the greatest zygosity separation between clusters (p=0.039, as evaluated via permutation testing). Furthermore, the subjects鈥� diagnosis corresponded sensibly with each cluster trajectory (even though the algorithm does not have information about diagnosis). The rapid decline cluster composes exclusively of subjects whose diagnosis start off being cognitive normal (CN) or MCI, then decline into dementia. Contrarily, the stable trajectory cluster mostly have individuals with unchanging diagnosis of either CN or MCI over multiple years. Interestingly, some MCI-diagnosed subjects were categorized into slow decline, while others into stable. Whether the slow decline MCI subset will end up developing dementia remains a follow- up question for future experiment.

The discovery that linear function fitting followed by unsupervised clustering yielded the best results is an elegant solution for the modelling of cognitive trajectory, as a polynomial function summarizes an arbitrary number of observations into a fixed number of descriptive features (polynomial coefficients). The fact that the linear model generated the best validation result may be two-fold. It may imply that cognitive decline occurs at an approximately linear rate. Similarly, it may be that there are not enough observations to fit a more complex model (e.g. higher degree polynomial) without overfitting. More data is needed to evaluate this.

Finally, we employed simple statistical learning algorithms to predict the subjects鈥� assigned cluster labels, using demographic, cognitive, CSF and genetic information at baseline, and changes in cognitive scores 12 months from baseline. Our best-performing model was logistic regression, identifying 64.8% of subjects who are declining, and the labels of 73.2% of subjects overall. While this is not state-of-the-art, this illustrates the feasibility of predicting data-driven cluster labels, and sets a baseline for future improvements. Our machine learning architecture can be made more sophisticated, and input features should also include the highly-informative neuroanatomical features (4,9,17).

In summary, this project illustrated a framework for the data-driven discovery of clinical sub- groups for any forms of degenerative illnesses, in which longitudinal clinical scores can be summarized through function fitting, and the coefficients provide the features for subsequent unsupervised clustering. In applying the above to AD, we contributed to the refinement of quantitatively defined cognitive trajectories in AD. Such trajectory definition allows for a better understanding of AD-related cognitive decline, in which patients may decline linearly at different rates into dementia, or stay cognitively healthy into their old age. Importantly, such cognitive trajectories can also be predicted at early stages, using a combination of demographic, protein and genetic features. This can be used in addition to clinical diagnosis to provide greater insight for future AD risk, allowing for early-intervention at a stage where heavy neuronal damage has not yet occurred. This will help reduce the trauma of AD in our aging population and AD-related externalities.

1. Alzheimer Association. 2017 Alzheimer鈥檚 disease facts and figures. Alzheimer鈥檚 Dement [Internet]. 2017;13(4):325鈥�73. Available from:
2. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer鈥檚 disease. Alzheimer鈥檚 and Dementia. 2018.
3. Bature F, Guinn BA, Pang D, Pappas Y. Signs and symptoms preceding the diagnosis of Alzheimer鈥檚 disease: A systematic scoping review of literature from 1937 to 2016. BMJ Open. 2017;7(8).
4. Bhagwat N, Viviano JD, Voineskos AN, Chakravarty MM, Initiative ADN. Modeling and prediction of clinical symptom trajectories in Alzheimer鈥檚 disease using longitudinal data. PLOS Comput Biol [Internet]. 2018;14(9):e1006376. Available from:
5. Crous-Bou M, Minguill贸n C, Gramunt N, Molinuevo JL. Alzheimer鈥檚 disease prevention: From risk factors to early intervention. Alzheimer鈥檚 Research and Therapy. 2017.
6. Olsson B, Lautner R, Andreasson U, 脰hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer鈥檚 disease: a systematic review and meta- analysis. Lancet Neurol. 2016;15(7):673鈥�84.
7. Selkoe DJ. Alzheimer鈥檚 Disease: Genes, Proteins, and Therapy. Physiol Rev. 2001;
8. Querbes O, Aubry F, Pariente J, Lotterie J-A, D茅monet J-F, Duret V, et al. Early diagnosis of Alzheimer鈥檚 disease using cortical thickness: impact of cognitive reserve. Brain [Internet]. 2009;132(8):2036鈥�47. Available from: lookup/doi/10.1093/brain/awp105
9. Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;
10. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol [Internet]. 2001 Mar;58(3):397鈥�405. Available from
11. Moradi E, Pepe A, Gaser C, Huttunen H, Tohka J. Machine learning framework for early MRI-based Alzheimer鈥檚 conversion prediction in MCI subjects. Neuroimage [Internet]. 2015;104:398鈥�412. Available from
12. Cheng B, Liu M, Suk H Il, Shen D, Zhang D. Multimodal manifold-regularized transfer learning for MCI conversion prediction. Brain Imaging Behav. 2015;9(4):913鈥�26.
13. Cheng B, Liu M, Shen D, Li Z, Zhang D. Multi-Domain Transfer Learning for Early Diagnosis of Alzheimer鈥檚 Disease. Neuroinformatics. 2017;15(2):115鈥�32.
14. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer鈥檚 Disease Assessment Scale that broaden its scope. The Alzheimer鈥檚 Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;
15. Arevalo-Rodriguez I, Smailagic N, Roqu茅 I Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer鈥檚 disease and other dementias in people with mild cognitive impairment (MCI). Cochrane database Syst Rev [Internet]. 2015 Mar 5;(3):CD010783. Available from: